menu
    • menu
    [{"orgOrder":0,"company":"Kemwell Biopharma Private Limited","sponsor":"RevOpsis Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RevOpsis and Kemwell Form Strategic Manufacturing Partnership for Biologics","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"RO-104","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kemwell Biopharma Private Limited","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kemwell Biopharma Private Limited \/ RevOpsis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Kemwell Biopharma Private Limited \/ RevOpsis Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Kemwell Biopharma Private Limited

    Menu

    Kemwell Biopharma Private Limited

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kemwell Biopharma Private Limited

                            Sweden arrow
                            FNCE 2024
                            Not Confirmed

                            Kemwell Biopharma Private Limited

                            Sweden arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RO-104

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Sponsor : RevOpsis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            RevOpsis and Kemwell Form Strategic Manufacturing Partnership for Biologics

                            Details : Through the partnership, RevOpsis is well-positioned to advance the clinical development of RO-104, a first-in-class lead candidate for the treatment of neovascular age-related macular degeneration.

                            Brand Name : RO-104

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 17, 2024

                            Lead Product(s) : RO-104

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Sponsor : RevOpsis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth